

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: <https://www.coronavirus.gov>.

Get the latest research from NIH: <https://www.nih.gov/coronavirus>.

Find NCBI SARS-CoV-2 literature, sequence, and clinical content: <https://www.ncbi.nlm.nih.gov/sars-cov-2/>.

Similar Articles for PMID: 32157927

111 results

1 Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.

Artini PG, Obino MER, Micelli E, Malacarne E, Vacca C, Papini F, Cela V.

Gynecol Endocrinol. 2020 Sep;36(9):755-759. doi: 10.1080/09513590.2020.1737007. Epub 2020 Mar 11.

PMID: 32157927

2 Targeting Metabolic Consequences of Insulin Resistance in Polycystic Ovary Syndrome by D-chiro-inositol and Emerging Nutraceuticals: A Focused Review.

Davinelli S, Nicolosi D, Di Cesare C, Scapagnini G, Di Marco R.

J Clin Med. 2020 Apr 2;9(4):987. doi: 10.3390/jcm9040987.

PMID: 32252239 [Free PMC article](#). Review.

3 Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.

Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, Prati A, Simoncini T.

Gynecol Endocrinol. 2014 Jun;30(6):438-43. doi: 10.3109/09513590.2014.897321. Epub 2014 Mar 7.

PMID: 24601829 Clinical Trial.

4 Inositol for subfertile women with polycystic ovary syndrome.

Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C.

Cochrane Database Syst Rev. 2018 Dec 20;12(12):CD012378. doi: 10.1002/14651858.CD012378.pub2.

PMID: 30570133 [Free PMC article](#).

5 d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.

Cianci A, Panella M, Fichera M, Falducci C, Bartolo M, Caruso S.

Gynecol Endocrinol. 2015 Jun;31(6):483-6. doi: 10.3109/09513590.2015.1014784. Epub 2015 Apr 20.

PMID: 25893270

6 CONCERN: Does ovary need D-chiro-inositol?

Isabella R, Raffone E.

J Ovarian Res. 2012 May 15;5(1):14. doi: 10.1186/1757-2215-5-14.

PMID: 22587479 [Free PMC article](#).

7 Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.

Monastra G, Unfer V, Harrath AH, Bizzarri M.

Gynecol Endocrinol. 2017 Jan;33(1):1-9. doi: 10.1080/09513590.2016.1247797. Epub 2016 Nov 29.

PMID: 27898267 Review.

8 Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.

Genazzani AD, Prati A, Marchini F, Petrillo T, Napolitano A, Simoncini T.

Gynecol Endocrinol. 2019 Dec;35(12):1088-1093. doi: 10.1080/09513590.2019.1640200. Epub 2019 Jul 13.

PMID: 31304823

9 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

- Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH.
Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6.
PMID: 29183107 [Free PMC article](#). Review.
- 10 **Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature.**
Regidor PA, Schindler AE, Lesoine B, Druckman R.
Horm Mol Biol Clin Investig. 2018 Mar 2;34(2):j/hmbci.2018.34.issue-2/hmbci-2017-0067/hmbci-2017-0067.xml. doi: 10.1515/hmbci-2017-0067.
PMID: 29498933 Review.
- 11 **Efficacy of combination therapy of inositol, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.**
Advani K, Batra M, Tajpuriya S, Gupta R, Saraswat A, Nagar HD, Makwana L, Kshirsagar S, Kaul P, Ghosh AK, Pradhan S, Mehta A, Jaiswal A, Nakhate KT, Kamdi S.
J Obstet Gynaecol. 2020 Jan;40(1):96-101. doi: 10.1080/01443615.2019.1604644. Epub 2019 Jul 24.
PMID: 31339394
- 12 **D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.**
Galazis N, Galazi M, Atiomo W.
Gynecol Endocrinol. 2011 Apr;27(4):256-62. doi: 10.3109/09513590.2010.538099. Epub 2010 Dec 10.
PMID: 21142777 Review.
- 13 **Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.**
Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE.
Metab Syndr Relat Disord. 2010 Apr;8(2):127-36. doi: 10.1089/met.2009.0052.
PMID: 20156067 [Free PMC article](#). Clinical Trial.
- 14 **Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.**
Frizzetti F, Capozzi A, Canu A, Lello S.
Gynecol Endocrinol. 2019 Jun;35(6):506-510. doi: 10.1080/09513590.2018.1540573. Epub 2019 Jan 7.
PMID: 30612488
- 15 **Inositol as putative integrative treatment for PCOS.**
Genazzani AD.
Reprod Biomed Online. 2016 Dec;33(6):770-780. doi: 10.1016/j.rbmo.2016.08.024. Epub 2016 Sep 16.
PMID: 27717596 [Free article](#). Review.
- 16 **Inositol's Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.**
Wojciechowska A, Osowski A, Jóźwik M, Górecki R, Rynkiewicz A, Wojtkiewicz J.
Int J Mol Sci. 2019 Nov 18;20(22):5787. doi: 10.3390/ijms20225787.
PMID: 31752081 [Free PMC article](#). Review.
- 17 **The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.**
Nordio M, Proietti E.
Eur Rev Med Pharmacol Sci. 2012 May;16(5):575-81.
PMID: 22774396 Clinical Trial.
- 18 **Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.**
Laganà AS, Garzon S, Casarin J, Franchi M, Ghezzi F.
Trends Endocrinol Metab. 2018 Nov;29(11):768-780. doi: 10.1016/j.tem.2018.09.001. Epub 2018 Sep 27.
PMID: 30270194 Review.
- 19 **Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositol.**
Sortino MA, Salomone S, Carruba MO, Drago F.
Front Pharmacol. 2017 Jun 8;8:341. doi: 10.3389/fphar.2017.00341. eCollection 2017.
PMID: 28642705 [Free PMC article](#). Review.

- 20 **Experts' opinion on inositol in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.**
Facchinetti F, Appeteccchia M, Aragona C, Bevilacqua A, Bezerra Espinola MS, Bizzarri M, D'Anna R, Dewailly D, Diamanti-Kandarakis E, Hernández Marín I, Kamenov ZA, Kandarakis E, Laganà AS, Monastra G, Montanino Oliva M, Nestler JE, Orio F, Ozay AC, Papalou O, Pkhadze L, Porcaro G, Prapas N, Soulage CO, Stringaro A, Wdowiak A, Unfer V.
Expert Opin Drug Metab Toxicol. 2020 Mar;16(3):255-274. doi: 10.1080/17425255.2020.1737675. Epub 2020 Mar 19.
PMID: 32129111
- 21 **The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.**
Colazingari S, Treglia M, Najjar R, Bevilacqua A.
Arch Gynecol Obstet. 2013 Dec;288(6):1405-11. doi: 10.1007/s00404-013-2855-3. Epub 2013 May 25.
PMID: 23708322 Clinical Trial.
- 22 **The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.**
Minozzi M, Nordio M, Pajalich R.
Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):537-40.
PMID: 23467955 [Free article](#).
- 23 **May myo-inositol and d-chiro-inositol (40:1) treatment be a good option on normal-weighted polycystic ovary syndrome patients without insulin resistance?**
Colak E, Ozcimen EE, Tohma YA, Ceran MU.
J Obstet Gynaecol Res. 2020 Sep 28. doi: 10.1111/jog.14505. Online ahead of print.
PMID: 32989863
- 24 **Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.**
Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V.
Minerva Ginecol. 2015 Oct;67(5):457-63.
PMID: 26491824 Clinical Trial.
- 25 **A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women.**
Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M.
Int J Endocrinol. 2016;2016:3204083. doi: 10.1155/2016/3204083. Epub 2016 Jul 14.
PMID: 27493664 [Free PMC article](#).
- 26 **D-Chiro-Inositol Treatment Affects Oocyte and Embryo Quality and Improves Glucose Intolerance in Both Aged Mice and Mouse Models of Polycystic Ovarian Syndrome.**
Pericuesta E, Laguna-Barraza R, Ramos-Ibeas P, Gutierrez-Arroyo JL, Navarro JA, Vera K, Sanjuan C, Baixeras E, de Fonseca FR, Gutierrez-Adan A.
Int J Mol Sci. 2020 Aug 22;21(17):6049. doi: 10.3390/ijms21176049.
PMID: 32842637 [Free PMC article](#).
- 27 **[Evaluation of the treatment with D-chiro-inositol on levels of oxidative stress in PCOS patients].**
De Leo V, La Marca A, Cappelli V, Stendardi A, Focarelli R, Musacchio MC, Piomboni P.
Minerva Ginecol. 2012 Dec;64(6):531-8.
PMID: 23232537 Clinical Trial. Italian.
- 28 **Potential role and therapeutic interests of myo-inositol in metabolic diseases.**
Croze ML, Soulage CO.
Biochimie. 2013 Oct;95(10):1811-27. doi: 10.1016/j.biochi.2013.05.011. Epub 2013 Jun 10.
PMID: 23764390 Review.
- 29 **The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.**
Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M.
J Clin Pharmacol. 2014 Oct;54(10):1079-92. doi: 10.1002/jcpb.362. Epub 2014 Jul 18.

PMID: 25042908 Review.

30 [The inositol and polycystic ovary syndrome.](#)

Kalra B, Kalra S, Sharma JB.

Indian J Endocrinol Metab. 2016 Sep-Oct;20(5):720-724. doi: 10.4103/2230-8210.189231.

PMID: 27730087 [Free PMC article.](#)

31 [Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.](#)

Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE.

Diabetes Care. 2006 Feb;29(2):300-5. doi: 10.2337/diacare.29.02.06/dc05-1070.

PMID: 16443877

32 [Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial.](#)

Abdalmageed OS, Farghaly TA, Abdelaleem AA, Abdelmagied AE, Ali MK, Abbas AM.

Reprod Sci. 2019 Oct;26(10):1336-1342. doi: 10.1177/1933719118765985. Epub 2018 Mar 25.

PMID: 29576001 Clinical Trial.

33 [Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositol.](#)

Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, Granese R, Triolo O.

Int J Endocrinol. 2016;2016:6306410. doi: 10.1155/2016/6306410. Epub 2016 Aug 4.

PMID: 27579037 [Free PMC article.](#) Review.

34 [The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis.](#)

Bhide P, Pundir J, Gudi A, Shah A, Homburg R, Acharya G.

Acta Obstet Gynecol Scand. 2019 Oct;98(10):1235-1244. doi: 10.1111/aogs.13625. Epub 2019 May 20.

PMID: 30993683 [Free article.](#)

35 [Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.](#)

Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE.

J Clin Endocrinol Metab. 2004 Jan;89(1):242-9. doi: 10.1210/jc.2003-030437.

PMID: 14715857 Clinical Trial.

36 [Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study.](#)

Rago R, Marcucci I, Leto G, Caponechchia L, Salacone P, Bonanni P, Fiori C, Sorrenti G, Sebastianelli A.

J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):913-23.

PMID: 26753656

37 [Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome.](#)

Cheang KI, Baillargeon JP, Essah PA, Ostlund RE Jr, Apridonize T, Islam L, Nestler JE.

Metabolism. 2008 Oct;57(10):1390-7. doi: 10.1016/j.metabol.2008.05.008.

PMID: 18803944 [Free PMC article.](#) Clinical Trial.

38 [Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.](#)

Mendoza N, Diaz-Ropero MP, Aragon M, Maldonado V, Llaneza P, Lorente J, Mendoza-Tesarik R, Maldonado-Lobon J, Olivares M, Fonolla J.

Gynecol Endocrinol. 2019 Aug;35(8):695-700. doi: 10.1080/09513590.2019.1576620. Epub 2019 Mar 16.

PMID: 30880505 Clinical Trial.

39 [Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome.](#)

Gupta A, Jakubowicz D, Nestler JE.

- Metab Syndr Relat Disord. 2016 Oct;14(8):391-396. doi: 10.1089/met.2016.0009. Epub 2016 Mar 30.
PMID: 27028341 [Free PMC article](#). Clinical Trial.
- 40 **Myo-inositol vs. D-chiro inositol in PCOS treatment.**
Formuso C, Stracquadanio M, Ciotta L.
Minerva Ginecol. 2015 Aug;67(4):321-5. Epub 2015 Feb 11.
PMID: 25670222 Clinical Trial.
- 41 **Reflections on inositol(s) for PCOS therapy: steps toward success.**
Nestler JE, Unfer V.
Gynecol Endocrinol. 2015 Jul;31(7):501-5. doi: 10.3109/09513590.2015.1054802. Epub 2015 Jul 15.
PMID: 26177098 Review.
- 42 **The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study.**
La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A.
Gynecol Endocrinol. 2015 Jan;31(1):52-6. doi: 10.3109/09513590.2014.964201. Epub 2014 Sep 30.
PMID: 25268566
- 43 **High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.**
Mendoza N, Galan MI, Molina C, Mendoza-Tesarik R, Conde C, Mazheika M, Diaz-Ropero MP, Fonolla J, Tesarik J, Olivares M.
Gynecol Endocrinol. 2020 May;36(5):398-401. doi: 10.1080/09513590.2019.1681959. Epub 2019 Oct 26.
PMID: 31657275
- 44 **Inositol in Polycystic Ovary Syndrome: An Overview on the Advances.**
Facchinetto F, Unfer V, Dewailly D, Kamenov ZA, Diamanti-Kandarakis E, Laganà AS, Nestler JE, Soulage CO; Group of 'Inositol in PCOS and Reproduction'.
Trends Endocrinol Metab. 2020 Jun;31(6):435-447. doi: 10.1016/j.tem.2020.02.002. Epub 2020 Mar 9.
PMID: 32396844 Review.
- 45 **Effect on Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator during Weight Loss in Obese Women with and without Polycystic Ovary Syndrome.**
Cheang KI, Sistrun SN, Morel KS, Nestler JE.
Int J Endocrinol. 2016;2016:7631804. doi: 10.1155/2016/7631804. Epub 2016 Sep 18.
PMID: 27721826 [Free PMC article](#).
- 46 **Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositol metabolism.**
Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E.
Hum Reprod. 2008 Jun;23(6):1439-46. doi: 10.1093/humrep/den097. Epub 2008 Mar 29.
PMID: 18375940 [Free PMC article](#).
- 47 **Inositol Treatment and ART Outcomes in Women with PCOS.**
Garg D, Tal R.
Int J Endocrinol. 2016;2016:1979654. doi: 10.1155/2016/1979654. Epub 2016 Oct 4.
PMID: 27795706 [Free PMC article](#). Review.
- 48 **Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study.**
Troisi J, Cinque C, Giugliano L, Symes S, Richards S, Adair D, Cavallo P, Sarno L, Scala G, Caiazza M, Guida M.
J Ovarian Res. 2019 Mar 23;12(1):25. doi: 10.1186/s13048-019-0500-x.
PMID: 30904021 [Free PMC article](#). Clinical Trial.
- 49 **Breakthroughs in the Use of Inositol for Assisted Reproductive Treatment (ART).**
Facchinetto F, Espinola MSB, Dewailly D, Ozay AC, Prapas N, Vazquez-Levin M, Wdowiak A, Unfer V; Expert Group on Inositol in Preclinical and Clinical Research.
Trends Endocrinol Metab. 2020 Aug;31(8):570-579. doi: 10.1016/j.tem.2020.04.003. Epub 2020 May 15.
PMID: 32418772 Review.

- 50 **Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials.**
Laganà AS, Vitagliano A, Noventa M, Ambrosini G, D'Anna R.
Arch Gynecol Obstet. 2018 Oct;298(4):675-684. doi: 10.1007/s00404-018-4861-y. Epub 2018 Aug 4.
PMID: 30078122
- 51 **Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes.**
Cela V, Obino MER, Alberga Y, Pinelli S, Sergiampietri C, Casarosa E, Simi G, Papini F, Artini PG.
Gynecol Endocrinol. 2018 Jun;34(6):518-523. doi: 10.1080/09513590.2017.1412429. Epub 2017 Dec 22.
PMID: 29271274
- 52 **A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes.**
Maurizi AR, Menduni M, Del Toro R, Kyanvash S, Maggi D, Guglielmi C, Pantano AL, Defeudis G, Fioriti E, Manfrini S, Pozzilli P.
Acta Diabetol. 2017 Apr;54(4):361-365. doi: 10.1007/s00592-016-0954-x. Epub 2016 Dec 30.
PMID: 28039583 Clinical Trial.
- 53 **Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).**
Januszewski M, Issat T, Jakimiuk AA, Santor-Zaczynska M, Jakimiuk AJ.
Ginekol Pol. 2019;90(1):7-10. doi: 10.5603/GP.2019.0002.
PMID: 30756365 Free article.
- 54 **HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA).**
Cirillo F, Catellani C, Lazzeroni P, Sartori C, Tridenti G, Vezzani C, Fulghesu AM, Madeddu E, Amarri S, Street ME.
Gynecol Endocrinol. 2020 Jul;36(7):588-593. doi: 10.1080/09513590.2020.1725967. Epub 2020 Feb 13.
PMID: 32054355
- 55 **Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.**
Unfer V, Porcaro G.
Expert Rev Clin Pharmacol. 2014 Sep;7(5):623-31. doi: 10.1586/17512433.2014.925795. Epub 2014 Jun 5.
PMID: 24898153 Review.
- 56 **The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.**
Gateva A, Unfer V, Kamenov Z.
Gynecol Endocrinol. 2018 Jul;34(7):545-550. doi: 10.1080/09513590.2017.1421632. Epub 2018 Jan 8.
PMID: 29309199 Review.
- 57 **Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.**
Facchinetto F, Bizzarri M, Benvenga S, D'Anna R, Lanzone A, Soulage C, Di Renzo GC, Hod M, Cavalli P, Chiu TT, Kamenov ZA, Bevilacqua A, Carlomagno G, Gerli S, Oliva MM, Devroey P.
Eur J Obstet Gynecol Reprod Biol. 2015 Dec;195:72-6. doi: 10.1016/j.ejogrb.2015.09.024. Epub 2015 Oct 3.
PMID: 26479434
- 58 **Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.**
Paul C, Laganà AS, Maniglio P, Triolo O, Brady DM.
Gynecol Endocrinol. 2016 Jun;32(6):431-8. doi: 10.3109/09513590.2016.1144741. Epub 2016 Feb 29.
PMID: 26927948
- 59 **Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity.**
Villeneuve MC, Ostlund RE Jr, Baillargeon JP.
Metabolism. 2009 Jan;58(1):62-8. doi: 10.1016/j.metabol.2008.08.007.
PMID: 19059532

- 60 [Evaluation of a new association between insulin-sensitizers and α -lipoic acid in obese women affected by PCOS].
Cappelli V, Di Sabatino A, Musacchio MC, De Leo V.
Minerva Ginecol. 2013 Aug;65(4):425-33.
PMID: 24051942 Clinical Trial. Italian.
- 61 Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A, Laganà AS, Barbaro L.
Gynecol Endocrinol. 2014 Mar;30(3):205-8. doi: 10.3109/09513590.2013.860120. Epub 2013 Dec 19.
PMID: 24351072 Clinical Trial.
- 62 Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials.
Mendoza N, Pérez L, Simoncini T, Genazzani A.
Reprod Biomed Online. 2017 Nov;35(5):529-535. doi: 10.1016/j.rbmo.2017.07.005. Epub 2017 Jul 14.
PMID: 28756130 Review.
- 63 Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G.
N Engl J Med. 1999 Apr 29;340(17):1314-20. doi: 10.1056/NEJM199904293401703.
PMID: 10219066 Free article. Clinical Trial.
- 64 Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
Galletta M, Grasso S, Vaiarelli A, Roseff SJ.
Eur Rev Med Pharmacol Sci. 2011 Oct;15(10):1212-4.
PMID: 22165685
- 65 Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
Nestler JE, Jakubowicz DJ, Iuorno MJ.
J Pediatr Endocrinol Metab. 2000;13 Suppl 5:1295-8.
PMID: 11117673 Review.
- 66 Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary.
Roseff S, Montenegro M.
Int J Endocrinol. 2020 Mar 27;2020:6461254. doi: 10.1155/2020/6461254. eCollection 2020.
PMID: 32308679 Free PMC article. Review.
- 67 The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.
Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, Stener-Victorin E, Fauser BC, Norman RJ, Teede H.
Hum Reprod Update. 2016 Nov;22(6):687-708. doi: 10.1093/humupd/dmw025. Epub 2016 Aug 10.
PMID: 27511809 Review.
- 68 Effect of a Combination of Myo-Inositol, Alpha-Lipoic Acid, and Folic Acid on Oocyte Morphology and Embryo Morphokinetics in non-PCOS Overweight/Obese Patients Undergoing IVF: A Pilot, Prospective, Randomized Study.
Canosa S, Paschero C, Carosso A, Leoncini S, Mercaldo N, Gennarelli G, Benedetto C, Revelli A.
J Clin Med. 2020 Sep 12;9(9):2949. doi: 10.3390/jcm9092949.
PMID: 32932604 Free PMC article.
- 69 Effects of inositol and alpha lipoic acid combination for polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Lei W, Gao Y, Hu S, Liu D, Chen Q.
Medicine (Baltimore). 2020 Jul 24;99(30):e20696. doi: 10.1097/MD.00000000000020696.
PMID: 32791663 Free PMC article.

- 70 **Pregnancy outcomes of PCOS overweight/obese patients after controlled ovarian stimulation with the GnRH antagonist protocol and frozen embryo transfer.**
Chen R, Chen S, Liu M, He H, Xu H, Liu H, Du H, Wang W, Xia X, Liu J.
Reprod Biol Endocrinol. 2018 Apr;16(1):36. doi: 10.1186/s12958-018-0352-z.
PMID: 29636081 [Free PMC article.](#)
- 71 **Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.**
Stracquadanio M, Ciotta L, Palumbo MA.
Gynecol Endocrinol. 2018 Jun;34(6):495-501. doi: 10.1080/09513590.2017.1418852. Epub 2017 Dec 21.
PMID: 29265900
- 72 **AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.**
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society.
Endocr Pract. 2015 Dec;21(12):1415-26. doi: 10.4158/EP15748.DSCPT2.
PMID: 26642102 Review.
- 73 **Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.**
Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S.
Eur Rev Med Pharmacol Sci. 2011 Apr;15(4):452-7.
PMID: 21608442 Clinical Trial.
- 74 **Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.**
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.
Cochrane Database Syst Rev. 2012 May 16;(5):CD003053. doi: 10.1002/14651858.CD003053.pub5.
PMID: 22592687 [Updated.](#) Review.
- 75 **Relationships of plasma C-peptide and gender to the urinary excretion of inositol in older people.**
Campbell WW, Ostlund RE Jr, Joseph LJ, Farrell PA, Evans WJ.
Horm Metab Res. 2001 Jan;33(1):44-51. doi: 10.1055/s-2001-12626.
PMID: 11280715
- 76 **Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome.**
Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE.
Endocr Pract. 2002 Nov-Dec;8(6):417-23. doi: 10.4158/EP.8.6.417.
PMID: 15251831 Clinical Trial.
- 77 **Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients.**
Genazzani AD, Shefer K, Della Casa D, Prati A, Napolitano A, Manzo A, Despini G, Simoncini T.
J Endocrinol Invest. 2018 May;41(5):583-590. doi: 10.1007/s40618-017-0782-z. Epub 2017 Oct 31.
PMID: 29090431
- 78 **The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.**
Zhu X, Ye H, Fu Y.
Medicine (Baltimore). 2016 Jul;95(28):e4193. doi: 10.1097/MD.00000000000004193.
PMID: 27428219 [Free PMC article.](#)
- 79 **D-chiro-inositol attenuates epinephrine-stimulated hepatic glucose output in the isolated perfused liver independently of insulin.**
Whiting L, Danaher RN, Ruggiero K, Lee CC, Chaussade C, Mulvey T, Phillips A, Loomes KM.
Horm Metab Res. 2013 May;45(5):394-7. doi: 10.1055/s-0032-1330016. Epub 2012 Dec 7.

PMID: 23225249

- 80 **Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation.**
Mostinckx L, Segers I, Belva F, Buyl R, Santos-Ribeiro S, Blockeel C, Smitz J, Anckaert E, Tournaye H, De Vos M.
Hum Reprod. 2019 Aug 1;34(8):1595-1607. doi: 10.1093/humrep/dez086.
PMID: 31347678
- 81 **Inositol: history of an effective therapy for Polycystic Ovary Syndrome.**
Bizzarri M, Carlomagno G.
Eur Rev Med Pharmacol Sci. 2014 Jul;18(13):1896-903.
PMID: 25010620 [Free article](#).
- 82 **Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.**
Lam UD, Lerchbaum E, Schweighofer N, Trummer O, Eberhard K, Genser B, Pieber TR, Obermayer-Pietsch B.
Gene. 2014 Mar 10;537(2):245-52. doi: 10.1016/j.gene.2013.12.055. Epub 2014 Jan 2.
PMID: 24388959
- 83 **Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.**
Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG.
Gynecol Endocrinol. 2012 Dec;28(12):969-73. doi: 10.3109/09513590.2012.685205. Epub 2012 May 21.
PMID: 22612517 Clinical Trial.
- 84 **Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.**
Lord JM, Flight IH, Norman RJ.
Cochrane Database Syst Rev. 2003;(3):CD003053. doi: 10.1002/14651858.CD003053.
PMID: 12917943 [Updated](#). Review.
- 85 **A comparative study on the outcomes of in vitro fertilization between women with polycystic ovary syndrome and those with sonographic polycystic ovary-only in GnRH antagonist cycles.**
Kim YJ, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM, Kim JG, Moon SY.
Arch Gynecol Obstet. 2010 Aug;282(2):199-205. doi: 10.1007/s00404-010-1401-9. Epub 2010 Feb 25.
PMID: 20182736
- 86 **Ovulation induction in polycystic ovary syndrome.**
Vause TDR, Cheung AP; REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY COMMITTEE.
J Obstet Gynaecol Can. 2010 May;32(5):495-502. doi: 10.1016/S1701-2163(16)34504-2.
PMID: 20500959
- 87 **Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study.**
D'Amato G, Caringella AM, Stanziano A, Cantatore C, Palini S, Caroppo E.
Reprod Biol Endocrinol. 2018 Sep 14;16(1):89. doi: 10.1186/s12958-018-0405-3.
PMID: 30217209 [Free PMC article](#).
- 88 **Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS.**
Unfer V, Dinicola S, Laganà AS, Bizzarri M.
Int J Mol Sci. 2020 Sep 28;21(19):7157. doi: 10.3390/ijms21197157.
PMID: 32998310 [Free PMC article](#). Review.
- 89 **Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.**
De Cicco S, Immediata V, Romualdi D, Policola C, Tropea A, Di Florio C, Tagliaferri V, Scarinci E, Della Casa S, Lanzone A, Apa R.
Gynecol Endocrinol. 2017 Sep;33(9):698-701. doi: 10.1080/09513590.2017.1313972. Epub 2017 Apr 23.
PMID: 28434274

- 90 **Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.**
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003053. doi: 10.1002/14651858.CD003053.pub4.
PMID: 20091537 Updated. Review.
- 91 **Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?**
Malvasi A, Kosmas I, Mynbaev OA, Sparic R, Gustapane S, Guido M, Tinelli A.
Clin Ter. 2017 Jul-Aug;168(4):e240-e247. doi: 10.7417/T.2017.2013.
PMID: 28703838 Free article. Clinical Trial.
- 92 **In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.**
Siristatidis CS, Maheshwari A, Vaidakis D, Bhattacharya S.
Cochrane Database Syst Rev. 2018 Nov 15;11(11):CD006606. doi: 10.1002/14651858.CD006606.pub4.
PMID: 30480769 Free PMC article.
- 93 **Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.**
Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A.
Gynecol Endocrinol. 2007 Dec;23(12):700-3. doi: 10.1080/09513590701672405. Epub 2007 Oct 10.
PMID: 17952759 Clinical Trial.
- 94 **Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome.**
Ujvari D, Hulchiy M, Calaby A, Nybacka Å, Byström B, Hirschberg AL.
Hum Reprod. 2014 Jul;29(7):1526-35. doi: 10.1093/humrep/deu114. Epub 2014 May 19.
PMID: 24842895
- 95 **Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.**
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.
Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003053. doi: 10.1002/14651858.CD003053.pub3.
PMID: 19821299 Updated. Review.
- 96 **Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome.**
Le Donne M, Metro D, Alibrandi A, Papa M, Benvenega S.
Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2293-2301. doi: 10.26355/eurrev_201903_17278.
PMID: 30915778 Free article.
- 97 **[Clinical analysis of assistant treatment proposals for infertile women with polycystic ovary syndrome].**
Chen ZJ, Shi YH, Li Y, Gao Q, Sheng Y, Ma ZX.
Zhonghua Fu Chan Ke Za Zhi. 2008 Aug;43(8):571-5.
PMID: 19087489 Chinese.
- 98 **Inositols in the Treatment of Insulin-Mediated Diseases.**
Muscogiuri G, Palomba S, Laganà AS, Orio F.
Int J Endocrinol. 2016;2016:3058393. doi: 10.1155/2016/3058393. Epub 2016 Sep 8.
PMID: 27688754 Free PMC article. Review.
- 99 **Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.**
Durmus U, Duran C, Ecirli S.
J Endocrinol Invest. 2017 May;40(5):487-497. doi: 10.1007/s40618-016-0582-x. Epub 2016 Nov 12.
PMID: 27838846

100 **Clinical and Metabolic Effects of Alpha-Lipoic Acid Associated with Two Different Doses of Myo-Inositol in Women with Polycystic Ovary Syndrome.**

Fruzzetti F, Benelli E, Fidecicchi T, Tonacchera M.

Int J Endocrinol. 2020 Mar 19;2020:2901393. doi: 10.1155/2020/2901393. eCollection 2020.

PMID: 32256570 [Free PMC article](#).

101 **Inositol Supplementation in the Prevention of Gestational Diabetes Mellitus.**

Tahir F, Majid Z.

Cureus. 2019 Sep 16;11(9):e5671. doi: 10.7759/cureus.5671.

PMID: 31720147 [Free PMC article](#). Review.

102 **Inositol and metabolic disorders: From farm to bedside.**

Caputo M, Bona E, Leone I, Samà MT, Nuzzo A, Ferrero A, Aimaretti G, Marzullo P, Prodam F.

J Tradit Complement Med. 2020 Mar 24;10(3):252-259. doi: 10.1016/j.jtcme.2020.03.005. eCollection 2020 May.

PMID: 32670820 [Free PMC article](#). Review.

103 **D-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence.**

Condorelli RA, Barbagallo F, Calogero AE, Cannarella R, Crafa A, La Vignera S.

J Clin Med. 2020 May 7;9(5):1373. doi: 10.3390/jcm9051373.

PMID: 32392776 [Free PMC article](#).

104 **Myoinositol and D-Chiro Inositol in Improving Insulin Resistance in Obese Male Children: Preliminary Data.**

Mancini M, Andreassi A, Salvioni M, Pelliccione F, Mantellassi G, Banderali G.

Int J Endocrinol. 2016;2016:8720342. doi: 10.1155/2016/8720342. Epub 2016 Nov 1.

PMID: 27882052 [Free PMC article](#).

105 **Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells.**

Filippello A, Scamporrino A, Di Mauro S, Malaguarnera R, Di Pino A, Scicali R, Purrello F, Piro S.

Biomolecules. 2020 Oct 4;10(10):1404. doi: 10.3390/biom10101404.

PMID: 33020399 [Free PMC article](#).

106 **Inositol in Insulin Signaling and Glucose Metabolism.**

Bevilacqua A, Bizzarri M.

Int J Endocrinol. 2018 Nov 25;2018:1968450. doi: 10.1155/2018/1968450. eCollection 2018.

PMID: 30595691 [Free PMC article](#). Review.

107 **D-chiro-inositol as a treatment in plaque psoriasis: a randomized placebo-controlled clinical trial.**

Owczarczyk-Saczonek A, Czerwińska J, Wygonowska E, Kasprowicz-Furmańczyk M, Placek W.

Dermatol Ther. 2020 Nov 14:e14538. doi: 10.1111/dth.14538. Online ahead of print.

PMID: 33188584

108 **Inositol in Midlife.**

Kalra S, Kalra B.

J Midlife Health. 2018 Jan-Mar;9(1):36-38. doi: 10.4103/jmh.JMH_52_16.

PMID: 29628727 [Free PMC article](#).

109 **Corrigendum to "The Efficacy of Inositol and N-Acetyl Cysteine Administration (Ovaric HP) in Improving the Ovarian Function in Infertile Women with PCOS with or without Insulin Resistance".**

Sacchinelli A, Venturella R, Lico D, Di Cello A, Lucia A, Rania E, Cirillo R, Zullo F.

Obstet Gynecol Int. 2016;2016:2026056. doi: 10.1155/2016/2026056. Epub 2016 Aug 17.

PMID: 27630715 [Free PMC article](#).

110 **Inositol: reflections on how to choose the appropriate one for PCOS.**

Genazzani A.

Gynecol Endocrinol. 2020 Nov 10:1-2. doi: 10.1080/09513590.2020.1846697. Online ahead of print.

PMID: 33169639 No abstract available.

111 THE GRACELESS CHIRO.

[No authors listed]

Cal State J Med. 1921 Jun;19(6):257.

PMID: 18738494 [Free PMC article](#). No abstract available.